Long-term use of depot-norethisterone enanthate: effect on blood coagulation factors and menstrual bleeding patterns.
Fifty-six women using depot-norethisterone enanthate injections for contraception for 2 years or more were compared with a control group of 48 women not using hormonal contraception. No significant difference was found between the study group and controls for Factors VIIc and Antithrombin III. Factor Xc was reduced in women who had used the injections for over two but less than five years [controls: mean 90.3% SD31.2 vs users for 2-5 yr: 78.7% SD17.1, 95%CI difference in means -0.3, -22.9]. In the group using Net-En for five years or more, Factor Xc was significantly higher than in the control group, but only by 14% of the mean control value [users for over 5 yr: 103.2% SD15.2, 95%CI difference in means 3.1, 22.7]. Haemoglobin levels, red cell count and packed cell volume were higher in those using the injections than in the control group. Changes in the platelet count were not statistically significant. Twenty-three women using the injection agreed to keep menstrual diaries. Of these, 20 experienced amenorrhoea for more than two consecutive injection intervals (112 days). It is concluded that long-term use of norethisterone enanthate is not associated with any markedly deleterious effects on Factor VIIc, Xc, or antithrombin III or haemoglobin levels. Amenorrhoea of 4 months or more can be expected after two years of continuous use.
McEwan
J A
JA
Helen Brook Department of Family Planning, King's College Hospital, London, U.K.
Griffin
M
M
D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced; D000941:Antigens / Q000032:analysis; D000990:Antithrombin III / Q000032:analysis; D001779:Blood Coagulation Factors / Q000187:drug effects*; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D003692:Delayed-Action Preparations; D004906:Erythrocyte Count / Q000187:drug effects; D004911:Erythrocyte Volume / Q000187:drug effects; D005167:Factor VII / Q000032:analysis / Q000276:immunology; D005170:Factor X / Q000032:analysis; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007267:Injections; D008598:Menstruation / Q000187:drug effects*; D008875:Middle Aged; D009640:Norethindrone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D013997:Time Factors
D000941:Antigens; D001779:Blood Coagulation Factors; D003280:Contraceptives, Oral, Synthetic; D003692:Delayed-Action Preparations; D006454:Hemoglobins; C042580:factor VII clotting antigen; D000990:Antithrombin III; D005167:Factor VII; D005170:Factor X; C024319:norethindrone enanthate; D009640:Norethindrone